Mobia Medical (MOBI)

The company’s principal product is the Vivistim Paired Vagus Nerve Stimulation System. Vivistim is an implanted device system that delivers vagus nerve stimulation while a patient performs specific rehabilitation exercises under clinical supervision. The approach is intended to reinforce neuroplasticity during therapy and help patients regain upper-limb function after chronic stroke-related disability.

Mobia Medical sells primarily into the US stroke-care market, with customers including primary and comprehensive stroke centers and other specialised rehabilitation providers. Revenue is generated from sales of the Vivistim System and related components, meaning the company’s commercial progress depends on physician adoption, patient referrals, hospital purchasing decisions, reimbursement pathways, and the capacity of stroke centres to integrate the therapy into their rehabilitation programmes.

The company operates in a specialised segment of the medical technology industry where clinical evidence, regulatory compliance, surgeon and therapist training, and patient selection are central to growth. Its positioning is distinctive because it targets a long-term recovery phase in stroke care, an area where many survivors have limited treatment options after conventional rehabilitation plateaus. As a listed medical device company, Mobia Medical offers investors exposure to a focused neurorehabilitation platform with commercial traction tied to the expansion of Vivistim use in the United States.